NEW YORK (GenomeWeb News) – BioMarker Strategies has named Samuel Broder, Mark Velleca, and Paul Beresford to its board of directors. Broder was VP and CMO at Celera for a dozen years, and he is a former director of the National Cancer Institute. Velleca founded and was VP of CGI Pharmaceuticals. Beresford currently is VP of business development at Biodesix, and he formerly was VP of translational diagnostics at Ventana Medical Systems.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have an account?
Login Now.